Intravenous golimumab is both safe and effective over a one-year treatment period for patients with psoriatic arthritis. Rheumatologist Elaine Husnie, MD, MPH, discusses the findings.
Read MoreA New Biomarker for Disease Activity in Large Vessel Vasculitis
Current biomarkers used in giant cell arteritis (GCA) and Takayasu arteritis (TAK) are insufficiently specific for assessing disease activity. This study assessed whether S100 proteins were associated with disease activity in GCA and TAK.
CNS Granulomata in Common Variable Immunodeficiency
This case series adds to the diagnostic landscape of CNS granulomatous disease and provides an overview of the varying treatments currently in use for these rare manifestations of a rare disease.
Targeting Biomarkers of Nitric Oxide and Endothelial Dysfunction in RA and PsA
Translational work combining human plasma studies and previous mouse model data will enable identification of new, precise biomarkers and potential treatment pathways that may help pinpoint and treat RA and PsA patients at increased risk of CV disease.
Granulomatosis with Polyangiitis: A Persistent Risk Factor in Recurrent VTE
The rate of VTE recurrence in patients with GPA is similar to that of first VTE recurrence in patients with cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Connect with Cleveland Clinic at ACR 2017
Cleveland Clinic rheumatologists will present important research at this year’s meeting. Don’t miss these nine oral and poster presentations.
Managing Reproductive Health in Patients with SLE
Pregnant women with SLE with active disease and major organ involvement have a higher risk of thrombosis, premature delivery, preeclampsia, eclampsia, pregnancy loss and maternal mortality.
Eosinophilic Granulomatosis with Polyangiitis: A Disease at the Crossroads
This multisystemic disease mostly affects patients between 40 and 60 years old, and its prevalence is 10.7 to 13 cases per million. Often, the diagnosis of EGPA is complex and requires collaboration from different disciplines including pulmonology, rheumatology, allergy and cardiology.
RSLV-132: Help for Recalcitrant SLE?
RSLV-132 is not a first-line treatment, but it may be particularly promising for some of the 60 to 80 percent of lupus patients with skin manifestations.
Unique Tool Provides Validated Disease Activity Scores at the Point of Care
A new tool using a tablet and validated outcome measures has been initiated at Cleveland Clinic. It enables rheumatologists to obtain the information they need to make informed treatment decisions in real time and before they enter the patient’s room.
Update: Zika and Rheumatology
A brief update on Zika for practicing rheumatologists in North America.